News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Inspire Pharmaceuticals, Inc. Initiates Phase 2 14-Day Clinical Trial Of Epinastine For Seasonal Allergic Rhinitis
December 5, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today the initiation of a Phase 2 clinical trial to evaluate epinastine nasal spray for the treatment of seasonal allergic rhinitis.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Gene therapy
Regeneron Readies FDA Run for Hearing Loss Gene Therapy That Could ‘Transform Patients’ Lives’
October 13, 2025
·
2 min read
·
Tristan Manalac
Cancer
Moderna Claims Early Victory for Cancer Antigen in Melanoma
October 13, 2025
·
2 min read
·
Tristan Manalac
IN PARTNERSHIP WITH EVOTEC
Strategic Drug Development in a Funding Crisis: Expert Insights on Risk Profiling, Efficiency, and Innovation
October 13, 2025
·
8 min read
·
BioSpace Insights
IN PARTNERSHIP WITH CHARLES RIVER LABORATORIES
AI in CAR T Development: Lessons From the Front Lines
October 13, 2025
·
5 min read
·
BioSpace Insights
